Our portfolio

Amplio Pharma

Amplio Pharma’s proprietary NovoBio Med technology amplifies the efficacy of methotrexate (MTX), the first line, cornerstone drug used to treat a wide variety of autoimmune diseases. NovoBioMed is able to trap MTX at its target, resulting in a faster response and better efficacy at a lower dose.

Industry: Rheumatology, Therapeutics

Want to get in contact about Amplio Pharma?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Enabling secure AI-assisted data management, analysis, visualization, sharing, and FAIR publishing.
Engineering antibodies to treat neurodegenerative and immune diseases.
Automating urine output monitoring for hospitalized patients.
Developing novel treatments for Parkinson’s disease and dopamine disorders.
Enabling secure AI-assisted data management, analysis, visualization, sharing, and FAIR publishing.
Engineering antibodies to treat neurodegenerative and immune diseases.
Automating urine output monitoring for hospitalized patients.
Developing novel treatments for Parkinson’s disease and dopamine disorders.